ID.1
Item
each patient must meet all these criteria in order to be considered for enrollment in the phase i study:
boolean
ID.2
Item
histologically confirmed breast cancer and either clinical, radiological or laboratory evidence of metastatic disease.
boolean
C0678222 (UMLS CUI [1,1])
C0019638 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2])
ID.3
Item
patients must have received both anthracycline-containing and chemotherapy either as adjuvant treatment or therapy for metastatic breast cancer.
boolean
C0282564 (UMLS CUI [1])
C3541958 (UMLS CUI [2])
ID.4
Item
there is no limit on prior chemotherapy regimens or hormonal therapies received.
boolean
C0392920 (UMLS CUI [1,1])
C0449295 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2,1])
C0449295 (UMLS CUI [2,2])
ID.5
Item
concomitant bisphosphonate treatment is allowed for patients with bone metastases.
boolean
C0153690 (UMLS CUI [1])
ID.6
Item
patients must have recovered from acute toxic effects of any prior therapy including surgery and radiation.
boolean
C2004454 (UMLS CUI [1])
ID.7
Item
zubrod performance status < 2. (see appendix a)
boolean
C1518965 (UMLS CUI [1])
ID.8
Item
adequate bone marrow function: platelets > 100,000/mm3, anc > 1500 cells/mm3, hemoglobin > 8g/dl.
boolean
C0005821 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
ID.9
Item
normal renal function: creatinine < 2.0 mg/dl.
boolean
C0201976 (UMLS CUI [1])
ID.10
Item
adequate liver function: bilirubin < 1.5 mg/dl. transaminases (sgot) or ldh, and alkaline phosphatase must be <1.5 x of the upper limit of normal in the absence of bone or liver metastasis, or <2.5 x of the upper limit of normal in the presence of radiologically apparent liver metastasis or bone metastasis, respectively.
boolean
C1278039 (UMLS CUI [1])
C0002594 (UMLS CUI [2])
C0202113 (UMLS CUI [3])
C0201850 (UMLS CUI [4])
ID.11
Item
female patients must be of non-childbearing potential or non-lactating and using adequate contraception. beta-hcg will be checked in premenopausal patients if clinically indicated.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
ID.12
Item
patients with brain metastases whose disease remained for more than 6 months after completing therapy to the brain are eligible.
boolean
C0220650 (UMLS CUI [1])
C0205360 (UMLS CUI [2])
ID.13
Item
written informed consent.
boolean
C0021430 (UMLS CUI [1])
ID.14
Item
in addition to the above, patients participating in the phase ii portion of this study:
boolean
ID.15
Item
must have bidimensionally measurable or evaluable disease. lytic lesions seen on plain radiographs will be considered evaluable in conjunction with bone scan abnormalities. bone scan abnormalities alone, pure blastic bone metastases or irradiated lesions are not considered measurable or evaluable and will not be accepted. also, pleural or peritoneal effusions will not be considered evaluable disease.
boolean
C1513041 (UMLS CUI [1])
ID.16
Item
a patient must not be enrolled if any of the following criteria applies:
boolean
ID.17
Item
known hypersensitivity to sulindac (clinoril).
boolean
C0020517 (UMLS CUI [1,1])
C0038792 (UMLS CUI [1,2])
ID.18
Item
known hypersensitivity or contraindications to capecitabine (xelodar) including prior therapy with capecitabine.
boolean
C0671970 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
ID.19
Item
clinical or laboratory evidence of significant liver disease.
boolean
C0023895 (UMLS CUI [1])
ID.20
Item
concomitant treatment with cytotoxic agents other than capecitabine or participation in any other investigational study.
boolean
C0304497 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
ID.21
Item
uncontrolled psychiatric, or social (addictive) disorders that would preclude obtaining informed consent or patient participation in the study.
boolean
C0846574 (UMLS CUI [1])